Is Sabra Health Care REIT (SBRA) Still Below Fair Value On Rating And Coverage Moves?

Barclays has initiated coverage on Sabra Health Care REIT (SBRA) with an Equalweight rating, and S&P Global Ratings has shifted its outlook to positive, putting fresh attention on the healthcare focused real estate investment trust.

See our latest analysis for Sabra Health Care REIT.

At a share price of US$20.03, Sabra Health Care REIT has seen a 10.3% 1 month share price return and a 4.6% gain year to date, while its 1 year total shareholder return of 15.2% and very large 3 year total shareholder return suggest momentum has been building around the story of occupancy trends, tenant coverage and the shift toward senior housing.

If this healthcare REIT has your attention, it could be a good moment to broaden your watchlist with other long term compounders by checking out our screener of 19 top founder-led companies

Sabra Health Care REIT has clear momentum in senior housing, and credit quality is drawing fresh attention after the recent rating moves. The key question is whether those strengths are already reflected in the US$20 share price or if there is still a margin of safety.

Most Popular Narrative: 9.2% Undervalued

Sabra Health Care REIT's most followed valuation narrative puts fair value at about $22.07, compared with the recent $20.03 share price. This is drawing interest to how that gap is justified using a 7.77% discount rate.

The limited new development of senior housing driven by elevated construction and financing costs has created a supply-demand imbalance in key markets, giving Sabra pricing power for rent increases and occupancy gains, resulting in expanding margins and boosting net operating income.

Read the complete narrative.

Want to see what sits behind that valuation gap for Sabra Health Care REIT? The narrative leans on compounded revenue growth, firmer margins and a rich future earnings multiple. Curious which specific growth runway and earnings profile underpin that fair value path, and how sensitive it is to those assumptions? The full narrative lays out the numbers and the trade offs in detail.

Result: Fair Value of $22.07 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Sabra Health Care REIT's story could be tested if senior housing acquisitions dilute margins, or if reimbursement or regulatory changes pressure tenant coverage and rent collections.

Find out about the key risks to this Sabra Health Care REIT narrative.

Next Steps

With mixed signals around Sabra Health Care REIT's upside and its risk profile, it makes sense to move quickly and test the numbers yourself; a good place to start is by weighing the company's 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Sabra Health Care REIT?

If Sabra Health Care REIT is already on your radar, do not stop there. Use the Simply Wall St screener to spot other opportunities that fit your style.

• Target more stable potential returns by scanning for companies with resilient balance sheets and consistent fundamentals using the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for quality at a compelling price by reviewing companies highlighted in the 44 high quality undervalued stocks that align with your return and risk expectations.
• Spot future standouts early by checking the screener containing 19 high quality undiscovered gems before others catch on to their financial strength and potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.